References
- EnochDABygottJMDalyMLKarasJADaptomycinJ Infect20075520521317629567
- Novartis Europharm LtdSummary of Product Characteristics2009
- KanafaniZACoreyGRDaptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infectionsExpert Rev Anti Infect Ther2007517718417402833
- FieldingJHistory of penicillinLancet1980143446101381
- GotsJSThe detection of penicillinases-producing properties of microorganismsScience194510230917829682
- SmithJTHamilton-millerJMKnoxRIsoxazolyl penicillins and penicillinaseNature19621951300130113989490
- MoranGJKrishnadasanAGorwitzRJMethicillin-resistant S. aureus infections among patients in the emergency departmentN Engl J Med200635566667416914702
- DauwalderOLinaGDurandGEpidemiology of invasive methicillin-resistant Staphylococcus aureus clones collected in France in 2006 and 2007J Clin Microbiol2008463454345818667599
- HolmesAGannerMMcGuaneSPittTLCooksonBDKearnsAMStaphylococcus aureus isolates carrying Panton-Valentine leucocidin genes in England and Wales: frequency, characterization, and association with clinical diseaseJ Clin Microbiol2005432384239015872271
- ChiniVPetinakiEFokaAParatirasSDimitracopoulosGSpiliopoulouISpread of Staphylococcus aureus clinical isolates carrying Panton-Valentine leukocidin genes during a 3-year period in GreeceClin Microbiol Infect200612293416460543
- Ramdani-BouguessaNBesMMeugnierHDetection of methicillin-resistant Staphylococcus aureus strains resistant to multiple antibiotics and carrying the Panton-Valentine leukocidin genes in an Algiers hospitalAntimicrob Agents Chemother2006501083108516495274
- Centers of disease control and prevention national nosocomial infections surveillance system: MRSA among ICU patients1995–2004
- MicekSTAlternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infectionsClin Infect Dis200745Suppl 3S184S19017712745
- SivagnanamSDeleuDRed man syndromeCrit Care2003711912012720556
- Von DrygalskiDACurtisBRBougieDWVancomycin-induced immune thrombocytopeniaN Engl J Med200735690491017329697
- BlotSMRSA pneumonia: better outcome through continuous infusion of vancomycin?Crit Care Med2005332127212816148496
- BylBJacobsFWallemacqPVancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusionAntimicrob Agents Chemother2003472015201712760889
- DiFADe GaudioARNovelliAContinuous infusion of vancomycin in methicillin-resistant staphylococcus infectionChemotherapy19984463689444411
- SteinkrausGWhiteRFriedrichLVancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05J Antimicrob Chemother2007
- TenoverFCLancasterMVHillBCCharacterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptidesJ Clin Microbiol199836102010279542929
- KirstHAThompsonDGNicasTIHistorical yearly usage of vancomycinAntimicrob Agents Chemother199842130313049593175
- SilvermanJAOliverNAndrewTLiTResistance studies with daptomycinAntimicrob Agents Chemother2001451799180211353628
- WiedemannBTest results: characterising the antimicronial activity of daptomycinClin Microbiol Infect20061291416445719
- RoseWELMRJ: In vitro activity of daptomycin in combination with gentamycin and rifampicin against Staphylococcus aureus isolates with reduced susceptibility from the bacterial endocarditis trial [abstract]Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 17–20, 2007Chicago Illinois: A-794
- TallyFPDeBruinMFDevelopment of daptomycin for gram-positive infectionsJ Antimicrob Chemother20004652352611020247
- KirstHAThompsonDGNicasTIHistorical yearly usage of vancomycinAntimicrob Agents Chemother199842130313049593175
- Cubist Pharmaceuticals. Cubicin full prescribing information2006
- TedescoKLRybakMJDaptomycinPharmacotherapy200424415714740787
- LakeyJHPtakMFluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranesBiochemistry198827463946452844233
- SilvermanJAPerlmutterNGShapiroHMCorrelation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureusAntimicrob Agents Chemother2003472538254412878516
- DvorchikBHBrazierDDeBruinMFArbeitRDDaptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjectsAntimicrob Agents Chemother2003471318132312654665
- BushLMBosciaJAWendelerMPitsakisPGKayeDIn vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strainsAntimicrob Agents Chemother198933119812002552901
- HanbergerHNilssonLEMallerRIsakssonBPharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugsAntimicrob Agents Chemother199135171017161659305
- WiseRGeeTAndrewsJMDvorchikBMarshallGPharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteersAntimicrob Agents Chemother200246313311751107
- PrykaRDNovakRMWagnerDKRodvoldKAClinical pharmacokinetics of daptomycinDICP1990242552562156383
- TrotmanRLWilliamsonJCShoemakerDMSalzerWLAntibiotic dosing in critically ill adult patients receiving continuous renal replacement therapyClin Infect Dis2005411159116616163635
- OlesonFBJrBermanCLKirkpatrickJBReganKSLaiJJTallyFPOnce-daily dosing in dogs optimizes daptomycin safetyAntimicrob Agents Chemother2000442948295311036005
- ArbeitRDMakiDTallyFPCampanaroEEisensteinBIThe safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infectionsClin Infect Dis2004381673168115227611
- FigueroaDAMEA-GVBFCWWUCS-MS: Clinical safety with daptomycin at doses greater than 6 mg/kg [abstract]Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 17–20, 2007Chicago Illinois: A-792.
- PatelSJSamoTCSukiWNEarly-onset rhabdomyolysis related to daptomycin useInt J Antimicrob Agents20073047247417804204
- FowlerVGJrBoucherHWCoreyGRDaptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureusN Engl J Med200635565366516914701
- WeisFBeiras-FernandezASchellingGDaptomycin, a lipopeptide antibiotic in current clinical practiceCurr Opin Investig Drugs20089879884
- ArbeitRDMakiDTallyFPCampanaroEEisensteinBIThe safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infectionsClin Infect Dis2004381673168115227611
- OwensRCJrLampKCFriedrichLVRussoRPostmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycinAm J Med2007120S6S1217904950
- FowlerVGJrBoucherHWCoreyGRDaptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureusN Engl J Med200635565366516914701
- FalagasMEGiannopoulouKPNtzioraFPapagelopoulosPJDaptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidenceInt J Antimicrob Agents20073020220917459668
- AntonySJCombination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureusScand J Infect Dis20063829329516718933
- RaoNRegallaDMUncertain efficacy of daptomycin for prosthetic joint infections: a prospective case seriesClin Orthop Relat Res2006451343716735866
- FinneyMSCrankCWSegretiJUse of daptomycin to treat drug-resistant Gram-positive bone and joint infectionsCurr Med Res Opin2005211923192616368041
- FalagasMEGiannopoulouKPNtzioraFPapagelopoulosPJDaptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidenceInt J Antimicrob Agents20073020220917459668
- EifertSKronschnablSKaczmarekIReichartBVicolCOmental flap for recurrent deep sternal wound infection and mediastinitis after cardiac surgeryThorac Cardiovasc Surg20075537137417721846
- LampKCFriedrichLVMendez-VigoLRussoRClinical experience with daptomycin for the treatment of patients with osteomyelitisAm J Med2007120S13S2017904946
- CarlynCJBaltchALGeorgeMSmithRPDaptomycin in the treatment of persistent bacteremia with invasive complications caused bay a small colony variant of methicillin-resistant Staphylococcus aureus in an orthopedic patientInfect Dis Clin Pract200614394398
- CunhaBAEisensteinLEHamidNSPacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicityHeart Lung20063520721116701116
- CunhaBAHamidNKesslerHParchuriSDaptomycin cure after cefazolin treatment failure of Methicillin-sensitive Staphylococcus aureus (MSSA) tricuspid valve acute bacterial endocarditis from a peripherally inserted central catheter (PICC) lineHeart Lung20053444244716324966
- WeisFBeiras-FernandezAKaczmarekIDaptomycin for eradication of a systemic infection with a methicillin-resistant-Staphylococcus aureus in a biventricular assist device recipientAnn Thorac Surg20078426927017588430
- PresterlEKCRSLWGW: Activity of daptomycin and azithromycin against established biofilms formed by Staphylococcus epidermidis isolates in cardiac device infections [abstract]Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 17–20, 2007Chicago Illinois: K-1117.
- WagenlehnerFMLehnNWitteWNaberKGIn vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infectionsChemotherapy200551646915870498
- EnochDABygottJMDalyMLKarasJADaptomycinJ Infect20075520521317629567
- SilvermanJAMortinLIVanpraaghADLiTAlderJInhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impactJ Infect Dis20051912149215215898002
- VoornGPKuyvenhovenJGoessensWHRole of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycinAntimicrob Agents Chemother1994384874938203842
- SakoulasGEliopoulosGMAlderJEliopoulosCTEfficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother2003471714171812709345
- CaronFKitzisMDGutmannLDaptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faeciumAntimicrob Agents Chemother199236261126161336339
- RamosMCGraysonMLEliopoulosGMBayerASComparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococciAntimicrob Agents Chemother199236186418691329632
- CunhaBAEisensteinLEHamidNSPacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicityHeart Lung20063520721116701116
- FalagasMEGiannopoulouKPNtzioraFVardakasKZDaptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidenceJ Antimicrob Chemother20076071917550889
- MuangsiriWKirschLEThe protein-binding and drug release properties of macromolecular conjugates containing daptomycin and dextranInt J Pharm2006315304316546333
- NoelSPCourtneyHBumgardnerJDHaggardWOChitosan films: a potential local drug delivery system for antibioticsClin Orthop Relat Res20084661377138218421540